Hand, foot, and mouth disease (HFMD) is a common childhood illness characterized by fever and vesicular eruptions on hands and feet and in the mouth ([Figure 1](#F1){ref-type="fig"}). It is caused by members of the family *Picornaviridae* in the genus *Enterovirus*. Complications are rare, but pneumonia, meningitis, or encephalitis may occur. Outbreaks of HFMD have been mainly caused by 2 types of enterovirus A species, coxsackievirus (CV) A16 (CVA16) or enterovirus 71 ([@R1]). Some outbreaks have been associated with CVA10, but only sporadic cases involving other members of the enterovirus A species have been reported ([@R2]*,*[@R3]).

![Vesicular eruptions in A) hand, B) foot, and C) mouth of a 6.5-year-old boy from Turku, Finland, with coxsackievirus (CV) A6 infection. Several of his fingernails shed 2 months after the pictures were taken. D) Onychomadesis in a 10-year-old boy from Seinäjoki, Finland, 2 months after hand, foot and mouth disease with CVA6 infection. Photographs courtesy of H. Kujari (A--C) and M. Linna (D).](09-0438-F1){#F1}

During fall 2008, a nationwide outbreak of HFMD occurred in daycare centers and schools in Finland, starting in August and continuing at least until the end of the year and possibly into the following year. From vesicle fluid specimens of hospitalized children, we identified the etiologic agent as coxsackievirus A6.

The Study
=========

In August 2008, vesicle fluid specimens were collected from 2 children and 1 parent with HFMD at the Central Hospital of Seinäjoki, Southern Ostrobothnia. Specimens were sent to the Department of Virology, University of Turku, for identification of the causative agent. After detection of CVA6 in these index cases, the virus was also found in specimens obtained from the Pirkanmaa Hospital District (Tampere), Turku University Hospital (Turku), Pori Central Hospital (Pori), and *Central-Ostrobothnia Central Hospital (Kokkola)* ([Table](#T1){ref-type="table"}).

###### Laboratory findings in clinical specimens and epidemiologic data for patients with CVA6 infections, Finland, 2008\*

  City or place, identification   Sampling date   Sex/age, y   Specimen type       Disease or signs      CVA6-VP1 RT-PCR   VP1 sequence   5′ NCR sequence
  ------------------------------- --------------- ------------ ------------------- --------------------- ----------------- -------------- -----------------
  Seinäjoki                                                                                                                               
  Fin/Se8717                      2008 Aug        M/1.3        Vesicle fluid       HFMD                  Pos               CVA6           CVA6
  Fin/Se8781                      2008 Aug        F/34         Vesicle fluid       HFMD                  Pos               CVA6           CVA6
  Fin/Se8841                      2008 Aug        M/0.9        Vesicle fluid       HFMD                  Pos               CVA6           CVA6
  Fin/Se8865                      2008 Aug        †            Feces               HFMD                  Pos               NR             CVA6
  Fin/Se8913                      2008 Sep        M/10         Throat swab         HFMD                  Pos               NR             CVA6
  Fin/Se8925                      2008 Sep        M/0.9        Throat swab         HFMD                  Pos               NR             CVA6
  Fin/Se8926                      2008 Sep        †            Vesicle fluid       HFMD                  Pos               CVA6           CVA6
  Fin/Se8927                      2008 Sep        F/1.3        Throat swab         HFMD                  Pos               NR             CVA6
  Fin/Se8928                      2008 Sep        †            Vesicle fluid       HFMD                  Pos               CVA6           CVA6
  Fin/Se8931                      2008 Sep        M/0.8        Throat swab         NA                    Pos               NR             CVA6
  Turku                                                                                                                                   
  Fin/Tu8859                      2008 Sep        M/5.8        Throat swab         Fever, tonsillitis    Pos               CVA6           CVA6
  Fin/Tu8866                      2008 Sep        M/3.1        Throat swab         HFMD                  Pos               NR             CVA6
  Fin/Tu81027                     2008 Oct        M/1.8        Throat swab         HFMD                  Pos               NR             CVA6
  Fin/Tu81042                     2008 Oct        M/1.8        Throat swab         Fever, eczema         Pos               NR             CVA6
  Fin/Tu81038                     2008 Oct        F/2.2        Throat swab         Fever, seizure        Pos               NR             CVA6
  Fin/Tu81274                     2008 Nov        M/6.5        Vesicle fluid       HFMD                  Pos               ND             CVA6
  Fin/Tu81309                     2008 Dec        F/3.7        Vesicle fluid       HFMD                  Pos               ND             CVA6
  Fin/Tu81321                     2008 Dec        F/1.2        Throat swab         HFMD                  Pos               ND             NR
  Fin/Tu963                       2009 Jan        M/1.2        Throat swab         HFMD                  Pos               ND             CVA6
  Fin/Tu/IB                       2009 Feb        F/5.7        Nail                Recent HFMD           Pos               ND             CVA6
  Pori                                                                                                                                    
  Fin/Po8959                      2008 Oct        M/4.8        Throat              Fever, vomiting       Neg               ND             CVA6
  Fin/Po81375                     2008 Dec        M/0.5        Vesicle fluid       HFMD                  Pos               ND             CVA6
  Fin/Po81376                     2008 Dec        †            Throat              HFMD                  Pos               ND             CVA6
  Fin/Po81324                     2008 Dec        M/10         Feces               Fever, eczema         Pos               ND             NR
  Fin/Po81325                     2008 Dec        M/10         Feces               Fever, HFMD contact   Pos               ND             NR
  Tampere                                                                                                                                 
  Fin/Ta8966                      2008 Sep        M/3.1        Tracheal aspirate   NA                    Pos               NR             CVA6
  Fin/Ta81145                     2008 Sep        M/2.1        Feces               NA                    Pos               NR             NR
  Fin/Ta81074                     2008 Oct        M/0.3        Tracheal aspirate   NA                    Pos               ND             CVA6
  Fin/Ta81125                     2008 Oct        F/0.7        Vesicle fluid       HFMD                  Pos               CVA6           CVA6
  Fin/Ta81126                     2008 Oct        M/0.3        Vesicle fluid       HFMD                  Pos               NR             CVA6
  Fin/Ta81216                     2008 Nov        F/2.0        Throat swab         NA                    Pos               ND             CVA6
  Fin/Ta81252                     2008 Nov        M/6.1        Throat swab         NA                    Pos               ND             CVA6
  Kokkola                                                                                                                                 
  Fin/Ko937                       2009 Jan        M/10         Vesicle fluid       HFMD                  Pos               ND             CVA6

\*CVA6, coxsackievirus A6; VP1, virus protein 1; RT-PCR, reverse transcriptase--PCR; NCR, noncoding region; HFMD, hand, foot, and mouth disease; pos, positive; neg, negative; NA, not available; ND, not done; NR, no result (VP1 sequencing was attempted without result). †Same patient as on the line above.

Nucleic acids were extracted from specimens by using the NucliSens EasyMag automated extractor (bioMèrieux, Boxtel, the Netherlands). When the extracts were analyzed for enteroviruses by using real-time reverse transcriptase--PCR (RT-PCR) specific for the 5′ noncoding region (NCR) of picornaviruses ([@R4]), amplicons with melting points indistinguishable from each other and typical to enteroviruses were obtained.

To identify the enterovirus type in the specimens, RT-PCR, specific for a partial sequence of the viral protein 1 (VP1) region, was performed by using the COnsensus-DEgenerate Hybrid Oligonucleotide (CODEHOP) Primers (bioinformatics.weizmann.ac.il/blocks/codehop.html) ([@R5]). The amplicons were separated by agarose gel electrophoresis, purified with the QIAquick PCR Purification Kit (QIAGEN, Hilden, Germany), and sequenced in the DNA Sequencing Service Laboratory of the Turku Centre for Biotechnology. The virus type in the 3 index specimens, 3 samples of vesicular fluids, and 1 throat swab was successfully identified with sequencing and BLAST ([www.ncbi.nlm.gov/BLAST](http://www.ncbi.nlm.gov/BLAST)) analysis as CVA6. Phylogenetic relationships of the sequences were examined by using CVA6 (Gdula strain), CVA16 (G10), and enterovirus 71 (BrCr) prototype strains as well as selected clinical CVA6 isolates obtained from GenBank. Sequence alignments were generated with the ClustalW program ([www.ebi.ac.uk/clustalw](http://www.ebi.ac.uk/clustalw)), and the phylogenetic tree was computed by using the Jukes-Cantor algorithm and the neighbor-joining method. Phylogenetic analyses were conducted by using MEGA4 software ([www.megasoftware.net](http://www.megasoftware.net)) and the bootstrap consensus tree inferred from 1,000 replicates ([@R6]) ([Figure 2](#F2){ref-type="fig"}).

![Phylogenetic analysis of coxsackievirus (CV) A6 partial (289 bp) viral protein 1 sequences showing the relationships between the recent clinical CVA6 samples isolated in Finland (triangles), selected CVA6 isolates from GenBank, and prototypes of CVA6, CVA16, and enterovirus (EV) 71. GenBank accession numbers are included. Scale bar indicates nucleotide substitutions per position.](09-0438-F2){#F2}

Phylogenetic analysis placed all CVA6 strains from the HFMD outbreak in 1 cluster (97%--100% identity), whereas the nucleotide identities between those isolates and CVA6 prototype strains Gdula, CAV16, G-10, and enterovirus 71 BrCr were 82.5%--83.2%, 55.6%--56.6%, and 55.6%--57.3%, respectively. The closest preceding CVA6 strain was isolated from cerebrospinal fluid in the United Kingdom in 2007 and had 92%--94% nucleotide identity with the strains described here ([@R7]).

To improve the detection of the novel CVA6 strains in clinical specimens, we designed specific VP1 primers from the aligned sequences. CVA6vp1 reverse primer (5′-ACTCGCTGTGTGATGAATCG-3′) and CVA6vp1 forward primer (5′-CGTCAAAGCGCATGTATGTT-3′) generated a 199-bp amplicon. First, cDNA was synthesized in a 20-μL reaction mixture containing 1 μmol/L CVA6vp1 reverse primer, 2.5 mmol/L of each dNTP, 20 U RevertAid H Minus M-MuLV reverse transcriptase (Fermentas, St. Leon-Rot, Germany), reaction buffer (Fermentas), 4 U RiboLock RNase inhibitor (Fermentas), and 5 μL RNA incubated at 42ºC for 1 h. Then, 5 μL of cDNA was added to 20 μL of master mixture containing 0.4 μmol/L each of the CVA6vp1 primers and Maxima SYBR Green qPCR Master Mix (Fermentas). PCR with melting curve analysis was performed in a Rotor-Gene 6000 real-time instrument (Corbett Research, Mortlake, Victoria, Australia) by using the following cycling conditions: initial denaturation at 95ºC for 10 min, 45 cycles at 95ºC for 15 s, 60ºC for 30 s, and at 72ºC for 45 s, followed by generation of melting curve from 72°C to 95°C with temperature increments of 0.5°C/s. Partial 5′ NCR sequence of the strains in clinical specimens was determined as described ([@R4]) and compared with the known sequences by using BLAST (<http://blast.ncbi.nlm.nih.gov/Blast.cgi>).

During autumn 2008, a total of 47 acute-phase specimens, including 12 vesicle fluid samples, 23 throat swabs, 2 tracheal aspirates, 5 fecal samples, and 5 cerebrospinal fluid specimens from 43 patients yielded amplicons with similar melting points as the originally identified CVA6 strains in 5′ NCR RT-PCR. All specimens were subjected to the specific CVA6-VP1 real-time RT-PCR, and a positive result was obtained for 11 vesicle fluid samples, 14 throat swabs, 2 tracheal aspirates, and 4 fecal samples ([Table](#T1){ref-type="table"}). The virus in 1 throat swab was identified as CVA6 from the result of 5′ NCR sequencing alone. None of the CVA6-positive specimens were positive by an RT-PCR assay with CVA16- and EV71-specific primers ([@R8]). Attempts to cultivate the virus from 8 CVA6 RT-PCR-positive specimens were unsuccessful, whereas the prototype strain could be propagated in rhabdomyosarcoma cells.

Onychomadesis was 1 characteristic feature in patients during this HFMD outbreak; parents and clinicians reported that their children shed fingernails and/or toenails within 1--2 months after HFMD ([Figure 1](#F1){ref-type="fig"}). Only a few published reports of nail matrix arrest in children with a clinical history of HFMD exist in the medical literature ([@R9]*--*[@R11]). We obtained shed nails from 2 siblings who had HFMD 8 weeks before the nail shedding. The nail fragments were stored at --70°C for a few weeks and treated with proteinase K before nucleic acid extraction. The extracts were enterovirus positive in 5′ NCR RT-PCR. The virus in one of them was identified as CVA6 by the specific RT-PCR and yielded a 5′ NCR sequence that was similar to the novel CVA6 strains.

Conclusions
===========

Enterovirus CVA6 was a primary pathogen associated with HFMD during a nationwide outbreak in Finland in autumn of 2008. HFMD epidemics have primarily been associated with CVA16 or enterovirus 71 infections; those caused by enterovirus 71 have occurred more frequently in Southeast Asia and Australia in recent years ([@R12]). Reportedly, CVA10 has been found in minor outbreaks; other coxsackievirus A types have been found in only sporadic cases of HFMD ([@R2],[@R3]). In general, CVA6 infections have been seldom detected and mostly in association with herpangina ([@R13]*,*[@R14]). In Finland, CVA6 has been identified only on 4 occasions over 8 years during enterovirus surveillance from 2000 to 2007 ([@R15]).

Although the CODEHOP primers were elementary for rapid genotyping of the novel CVA6 strains, we identified more viruses with the designated CVA6-VP1 specific primers. Onychomadesis was a hallmark of this HFMD outbreak. To our surprise, we detected CVA6 also in a fragment of shed nail. The same virus could have given rise to the outbreak in Spain in 2008 ([@R10]). Supposedly, virus replication damages nail matrix and results in temporary nail dystrophy. Whether nail matrix arrest is specific to CVA6 infections remains to be shown. This study demonstrates that CVA6, in addition to CVA16 and enterovirus 71, may be emerging as a primary cause of HFMD.
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